A Phase 1b clinical trial of LDE225 (Sonidegib) in combination with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) in previously untreated locally advanced or metastatic pancreatic adenocarcinoma

Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital Cancer Center, Boston, MA, USA; Yale Cancer Center, New Haven, CT, USA; Dana Farber Cancer Institute, Boston, MA, USA; Dartmouth-Hitchcock Norris Cotton Cancer Center, One Medical Center Drive, Lebanon, NH, USA Contributions: (I) Conception and design: JW Clark, EL Kwak, TS Hong; (II) Administrative support: None; (III) Provision of study materials or patients: JW Clark, JN Allen, LS Blaszkowsky, JE Murphy, C Fuchs, BM Wolpin, RJ Mayer, JE Farris, JA Chan, K Ng, NJ McCleary, TA Abrams, DP Ryan, EL Kwak; (IV) Collection and assembly of data: JW Clark, N Horick, EL Kwak, TS Hong; (V) Data analysis and interpretation: JW Clark, N Horick, EL Kwak, TS Hong; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. These authors contributed equally to this work. Correspondence to: Jeffrey W. Clark, MD. Massachusetts General Hospital Cancer Center, 55 Fruit Street, 223 Bartlett Hall, Boston, MA 02114, USA. Email: clark.jeffrey@mgh.harvard.edu.